Search results for "Patents"

showing 10 items of 32 documents

Innovation in cardiovascular disease in Europe with focus on arrhythmias: current status, opportunities, roadblocks, and the role of multiple stakeho…

2018

The European Heart Rhythm Association (EHRA) held an Innovation Forum in February 2016, to consider issues around innovation. The objective of the forum was to extend the innovation debate outside of the narrow world of arrhythmia specialists and cardiology in general, and seek input from all stakeholders including regulators, strategists, technologists, industry, academia, health providers, medical societies, payers, and patients. Innovation is indispensable for a continuing improvement in health care, preferably at higher efficacy and lower costs. It requires people who have been trained in a good scientific environment, high-quality research for achieving ground breaking inventions and t…

0301 basic medicineBig Datamedia_common.quotation_subjectBig dataBasic scienceContext (language use)Disease030204 cardiovascular system & hematologyArrhythmias03 medical and health sciences0302 clinical medicinePhysiology (medical)Health careDevicesGeneticsMedicineInnovationReimbursementPatentsmedia_commonbusiness.industryComputer modelsCertaintyPublic relationsPersonalized medicineReimbursementElectrophysiologyClinical trial030104 developmental biologyCardiology and Cardiovascular MedicinebusinessRisk assessmentHealthcare providers
researchProduct

Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology

2020

Background: The therapeutic outcomes and the prognosis of patients with various hematologic malignancies are not always ideal with the current standard of care. Objective: The aim of this study is to analyze the results of the use of monoclonal antibodies, bispecific antibodies and antibody-drug conjugates for the therapy of malignant hemopathies. Methods: A mini-review was achieved using the articles published in Web of Science and PubMed between January 2017 and January 2020 and the new patents were made in this field. Results: Naked monoclonal antibodies have improved the therapeutic results obtained with standard of care, but they also have side effects and the use of some of them can …

0301 basic medicineCancer ResearchReceptor complexAntibody-drug conjugateImmunoconjugatesmedicine.drug_classmedicine.medical_treatmentAntineoplastic AgentsOfatumumabMonoclonal antibodyPatents as Topic03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAntigenObinutuzumabAntibodies BispecificDrug DiscoveryAnimalsHumansMedicinePharmacology (medical)Clinical Trials as Topicbusiness.industryAntibodies MonoclonalGeneral MedicineImmunotherapy030104 developmental biologyOncologychemistryHematologic Neoplasms030220 oncology & carcinogenesisMonoclonalCancer researchImmunotherapybusinessRecent Patents on Anti-Cancer Drug Discovery
researchProduct

Biopiracy of natural products and good bioprospecting practice

2016

Made available in DSpace on 2018-11-26T16:27:45Z (GMT). No. of bitstreams: 0 Previous issue date: 2016-02-15 Deutsche Forschungsgemeinschaft Background: Biopiracy mainly focuses on the use of biological resources and/or knowledge of indigenous tribes or communities without allowing them to share the revenues generated out of economic exploitation or other non-monetary incentives associated with the resource/knowledge. Methods: Based on collaborations of scientists from five continents, we have created a communication platform to discuss not only scientific topics, but also more general issues with social relevance. This platform was termed 'PhytCancer -Phytotherapy to Fight Cancer' (www.phy…

0301 basic medicineResource (biology)Drug IndustryInternational CooperationTheftPharmaceutical ScienceIntellectual property0603 philosophy ethics and religionIndigenousPatents as Topic03 medical and health sciencesIndigenous knowledgeDrug DiscoveryPatents as TopicTraditional knowledgeDeveloping CountriesPharmacologyBioprospectingBiological ProductsBioprospectingPlants Medicinalbusiness.industryIntellectual propertyCommercializationOwnership06 humanities and the artsPublic relationsBioethicsNatural resource030104 developmental biologyIncentiveComplementary and alternative medicineEthnopharmacologyMolecular MedicinePatent060301 applied ethicsBusiness
researchProduct

Earthquake-resistant construction techniques in Italy between 1880 and 1910: alternatives to reinforced concrete

2017

The series of earthquakes that struck Italy between the late nineteenth century and the first decade of the twentieth century spurred a lively debate about earthquake-resistant buildings that, through the influence of foreign experience, resulted in specialised literature and competitions that gave rise to a series of interesting patents. Innovative construction solutions for seismic areas were largely developed after the earthquake that struck the cities of Messina and Reggio Calabria in 1908, alongside the parallel advances in reinforced concrete. New earthquake-resistant construction solutions were based on a reassessment of traditional construction methods that used bricks, timber or me…

1908Earthquake-resistant construction; patents; Messina and Reggio Calabria earthquake; earthquake-resistant technology; 1908.patentsMessina and Reggio Calabria earthquakeearthquake-resistant technologyEarthquake-resistant construction patents Messina and Reggio Calabria earthquake earthquake-resistant technology 1908.Settore ICAR/18 - Storia Dell'ArchitetturaEarthquake-resistant construction
researchProduct

From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas an…

2017

Background Notable progress has been made in chemo- and immunotherapy of B-cell lymphomas, but less in the treatment of T-cell lymphomas. Objective Histone deacetylases inhibitors are a potentially useful therapeutic mean, as an epigenetic dysregulation is present in lymphomas, and especially in T-cell types. We aimed to study the progress made in this area. Method A mini-review was achieved using the articles published in PubMed in the last two years and the new patents made in this field. Results Histone deacetylases inhibitors are involved in the derepression of tumor suppressor genes through a histone deacetylase-mediated transcriptional process. Their inhibition is followed by cell cyc…

Cancer ResearchDrug exportmedicine.medical_treatmentCellular differentiationAntineoplastic Agents010402 general chemistryLymphoma T-Cell01 natural sciencesHistone DeacetylasesRomidepsinPatents as TopicDrug DiscoveryPlasma Cell MyelomamedicineAnimalsHumansPharmacology (medical)Epigeneticsbiology010405 organic chemistrybusiness.industryDrug SynergismGeneral MedicineImmunotherapymedicine.diseasePeripheral T-cell lymphoma0104 chemical sciencesHistone Deacetylase InhibitorsHistoneOncologyDrug DesignImmunologyCancer researchbiology.proteinbusinessMultiple Myelomamedicine.drugRecent patents on anti-cancer drug discovery
researchProduct

Biopiracy versus One-World Medicine-From colonial relicts to global collaborative concepts.

2017

Abstract Background Practices of biopiracy to use genetic resources and indigenous knowledge by Western companies without benefit-sharing of those, who generated the traditional knowledge, can be understood as form of neocolonialism. Hypothesis The One-World Medicine concept attempts to merge the best of traditional medicine from developing countries and conventional Western medicine for the sake of patients around the globe. Study design Based on literature searches in several databases, a concept paper has been written. Legislative initiatives of the United Nations culminated in the Nagoya protocol aim to protect traditional knowledge and regulate benefit-sharing with indigenous communiti…

Complementary TherapiesQuality ControlInternational CooperationPopulationPharmaceutical ScienceTheftLegislationSelf MedicationColonialismIndigenousPatents as Topic03 medical and health sciences0302 clinical medicineDouble-Blind MethodPolitical scienceDrug DiscoveryHealth careHumansNagoya ProtocolEuropean UnionTraditional knowledgeeducationDeveloping Countries030304 developmental biologyPharmacology0303 health scienceseducation.field_of_studyEvidence-Based MedicinePlants Medicinalbusiness.industryEvidence-based medicineBiodiversityPublic relationsComplementary and alternative medicine030220 oncology & carcinogenesisNaturopathyMolecular MedicineIntegrative medicineMedicine TraditionalbusinessPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Comment on the editorial ‘The secret ways of scientists’ in EMBO reports , December 2000

2001

I read ‘The secret ways of scientists’ with much interest and in principle I closely share the view expressed there. However, I am rather suspicious that such a view no longer reflects the truth. It appears to me that the tendency among scientists to start their own biotech companies may lead to a corruption of values and create a rather strange mixture of attitudes. The editorial states that ‘our …

Corruptionmedia_common.quotation_subjectPolitical sciencePatents as TopicGeneticsConflict of interestConfidentialitySocial value orientationsMolecular BiologyBiochemistryDrug industrymedia_commonLaw and economicsEMBO reports
researchProduct

[Pharmacogenomics of antiretrovirals].

2008

HIV infection is a serious but treatable disease, yet current treatment is limited by development of resistance and high rates of adverse drug reactions. Antiretroviral therapy is especially suitable for pharmacogenomic investigation as both drug exposure and treatment response can be reliably measured. Increasing knowledge about genes implicated in pharmacokinetics, mode of action, efficacy, and toxicity of drugs has already provided relevant results for clinical practice, for example: The strong association of the abacavir hypersensitivity reaction with HLA-B*5701 permits testing patients for the allele, and if present avoiding the drug and therefore preventing the reaction. Persons with …

CyclopropanesDrugEfavirenzPyridinesmedia_common.quotation_subjectAtazanavir SulfateDiseaseBioinformaticsDrug HypersensitivityPatents as Topicchemistry.chemical_compoundPharmacokineticsCentral Nervous System DiseasesHLA AntigensAbacavirDrug Resistance ViralDrug DiscoveryMedicineHumansGenetic Predisposition to DiseasePharmacology (medical)Genetic TestingNevirapineGlucuronosyltransferaseDyslipidemiasHyperbilirubinemiamedia_commonRitonavirbusiness.industryPatient SelectionArea under the curveOxidoreductases N-DemethylatingGeneral MedicineDideoxynucleosidesBenzoxazinesHypersensitivity reactionCytochrome P-450 CYP2B6Infectious DiseaseschemistryAnti-Retroviral AgentsPharmacogeneticsAlkynesPharmacogenomicsAryl Hydrocarbon HydroxylasesbusinessOligopeptidesmedicine.drugMedicina clinica
researchProduct

Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)

2021

Introduction: DNA-dependent protein kinase (DNA-PK) plays a crucial role in the repair of DSBs via non-homologous end joining (NHEJ). Several DNA-PK inhibitors are being investigated for potential anticancer treatment in clinical trials.Area covered: This review aims to give an overview of patents published since 2010 by analyzing the patent space and structure features of scaffolds used in those patents. It also discusses the recent clinical developments and provides perspectives on future challenges and directions in this field.Expert opinion: As a key component of the DNA damage response (DDR) pathway, DNA-PK appears to be a viable drug target for anticancer therapy. The clinical investi…

DNA damageCancer therapyDNA-Activated Protein Kinase01 natural sciencesPatents as Topic03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug DevelopmentNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDrug DiscoveryCombination strategyAnimalsHumansMedicineProtein kinase AProtein Kinase InhibitorsPharmacologybusiness.industryGeneral MedicineSmall molecule0104 chemical sciences010404 medicinal & biomolecular chemistrychemistryAnticancer treatment030220 oncology & carcinogenesisPARP inhibitorCancer researchbusinessDNADNA DamageExpert Opinion on Therapeutic Patents
researchProduct

Could resveratrol be a useful drug for the treatment of malignant hemopathies?

2013

Resveratrol is a poly-phenol with many beneficial effects: not only as an antioxidant, anti-inflammatory, and antiatherogenic agent, as well as a platelet aggregation inhibitor, but also as an antiproliferative and proapoptotic factor in various types of cancers. There are reviews about the mechanisms responsible for its effects in leukemia and lymphomas, emphasizing the chemosensitizing role of resveratrol, which allows overcoming the multidrug resistance of cancers. The action of resveratrol occurs preferentially on leukemic cells, and not on the normal ones. In addition, it is one of the few drugs that act on leukemic stem cells. If experimental results are promising, its application in …

DrugCancer Researchmedicine.medical_treatmentmedia_common.quotation_subjectAntineoplastic AgentsPharmacologyResveratrolAntioxidantsPatents as Topicchemistry.chemical_compoundNeoplasmsDrug DiscoveryStilbenesmedicineHumansPharmacology (medical)Antiatherogenic agentmedia_commonbusiness.industryGeneral Medicinemedicine.diseaseAntineoplastic Agents PhytogenicBioavailabilityLeukemiaOncologychemistryResveratrolHematologic NeoplasmsPlatelet aggregation inhibitorDrug Therapy CombinationStem cellbusinessAdjuvantRecent patents on anti-cancer drug discovery
researchProduct